

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number

WO 2025/186213 A8

(51) International Patent Classification:

A61K 31/4745 (2006.01) A61P 35/00 (2006.01)
A61K 45/06 (2006.01) A61K 47/68 (2017.01)
A61K 47/50 (2017.01)

(21) International Application Number:

PCT/EP2025/055765

(22) International Filing Date:

04 March 2025 (04.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

24161256.3 04 March 2024 (04.03.2024) EP
24201896.8 23 September 2024 (23.09.2024) EP

(71) Applicant: **DEBIOPHARM INTERNATIONAL S.A.**
[CH/CH]; Forum "après-demain", Chemin Messidor 5-7,
1006 Lausanne (CH).

(72) Inventors: **VASLIN CHESSEX, Anne**; c/o Debiopharm
International S.A., Forum "après-demain", Chemin Mes-
sidor 5-7, 1006 Lausanne (CH). **PIGGOTT, Luke**; c/

o Debiopharm International S.A., Forum "après-demain",
Chemin Messidor 5-7, 1006 Lausanne (CH). **RODRIGO
IMEDIO, Esteban**; c/o Debiopharm International S.A., Fo-
rum "après-demain", Chemin Messidor 5-7, 1006 Lausanne
(CH).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB**; Arabellastraße 30,
81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(54) Title: COMBINATION OF A WEE1 INHIBITOR AND A TOPOISOMERASE 1 INHIBITOR




Figure 1

(57) Abstract: Methods of treating cancer using a combination of a WEE1 inhibitor and a topoisomerase 1 inhibitor are provided.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

02 October 2025 (02.10.2025)

(15) Information about Correction:

see Notice of 02 October 2025 (02.10.2025)